SPM 928

Drug Profile

SPM 928

Latest Information Update: 25 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ARYx Therapeutics; Schwarz Pharma
  • Class
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 01 Aug 2003 Discontinued - Preclinical for Arrhythmias in USA (unspecified route)
  • 11 Jan 2000 Preclinical development for Arrhythmias in USA (Unknown route)
  • 10 Jan 2000 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top